79 completed. 79 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 79 | Completed 79 |
| Phase 2 | 13 | Completed 13 |
Follow Fibromyalgia: new trials by email Literature Review of Fibromyalgia trials Research Report on Fibromyalgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia Lidocaine and Dexamethasone, Normal Saline - Fibromyalgia | Phase 2 / Phase 3 | Completed | Sanliurfa Education and Research Hospital | 68 | 2025-06-01 | 2026-01-16 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet - Fibromyalgia | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 457 | 2022-04-06 | 2025-01-22 |
| Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management Digital ACT, Digital Symptom Tracker - Fibromyalgia | Phase 3 | Completed | Swing Therapeutics, Inc. | 275 | 2022-02-08 | 2023-06-15 |
| Cannabidiol for Fibromyalgia (The CANNFIB Trial) Cannabidiol, Placebo - Fibromyalgia | Phase 3 | Completed | Marius Henriksen | 200 | 2021-03-01 | 2024-03-25 |
| A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia TNX-102 SL, Placebo SL Tablet - Fibromyalgia | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 514 | 2020-07-22 | 2023-12-18 |
| The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia Endotoxin, Escherichia Coli, Magnetic Resonance Spectroscopy - Fibromyalgia | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 36 | 2020-03-11 | 2023-04-14 |
| A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia TNX-102 SL, Placebo SL Tablet - Fibromyalgia | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 503 | 2019-12-09 | 2022-08-08 |
| LDN and tDCS in Fibromyalgia Low-Dose Naltrexone, Transcranial Direct Current Stimulation, Placebo - Fibromyalgia | Phase 2 / Phase 3 | Completed | Centro Universitario La Salle | 92 | 2018-08-01 | 2020-08-06 |
| Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia Duloxetine, Escitalopram - Fibromyalgia | Phase 2 / Phase 3 | Completed | Shaheed Zulfiqar Ali Bhutto Medical University | 200 | 2018-04-09 | 2020-02-27 |
| Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome MBSR, FibroQol, TAU - Fibromyalgia Syndrome | Phase 3 | Completed | Fundació Sant Joan de Déu | 225 | 2016-01-01 | 2019-10-14 |
| A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients TNX-102 SL Tablet 2.8 mg - Primary Fibromyalgia | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 375 | 2015-08-04 | 2025-02-20 |
| Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease DS-5565, Placebo - Fibromyalgia | Phase 3 | Completed | Daiichi Sankyo | 56 | 2015-06-26 | 2020-11-24 |
| A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet - Fibromyalgia, Myofascial Pain Syndromes | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 519 | 2015-04-01 | 2025-02-07 |
| An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia DS-5565 - Pain Associated With Fibromyalgia | Phase 3 | Completed | Daiichi Sankyo | 2485 | 2015-02-04 | 2020-07-23 |
| Treatment of Pain Associated With Fibromyalgia DS-5565, Pregabalin, Placebo tablet - Pain Associated With Fibromyalgia | Phase 3 | Completed | Daiichi Sankyo | 1301 | 2015-01-16 | 2020-11-09 |
| Brain Response to Single Dose of Pregabalin in Fibromyalgia Pregabalin, Placebo - Fibromyalgia | Phase 2 / Phase 3 | Completed | Hospital de Clinicas de Porto Alegre | 27 | 2014-12-01 | 2018-02-08 |
| Treatment of Pain Associated With Fibromyalgia DS-5565, Pregabalin, Placebo tablet - Pain Associated With Fibromyalgia | Phase 3 | Completed | Daiichi Sankyo | 1270 | 2014-11-01 | 2020-11-09 |
| Treatment of Pain Associated With Fibromyalgia DS-5565, Pregabalin, Placebo tablet - Pain Associated With Fibromyalgia | Phase 3 | Completed | Daiichi Sankyo | 1293 | 2014-10-27 | 2020-11-09 |
| 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients TNX-102 SL - Primary Fibromyalgia | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 158 | 2013-12-01 | 2017-07-07 |
| BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) TNX-102 SL 2.8mg, Placebo - Primary Fibromyalgia | Phase 2 / Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 205 | 2013-09-01 | 2016-12-23 |
Showing 20 of 79. Sign in to see all of them.
Pain (16) · Chronic Pain (6) · Arthralgia (3) · Depression (3) · Fatigue (3) · Myalgia (3) · Osteoarthritis (3) · Arthritis (2) · Arthritis, Rheumatoid (2) · Fatigue Syndrome, Chronic (2) · Irritable Bowel Syndrome (2) · Musculoskeletal Diseases (2) · Sleep Initiation and Maintenance Disorders (2) · Agnosia (1)
Muscular Diseases (78) · Nervous System Diseases (78) · Neuromuscular Diseases (78) · Rheumatic Diseases (78) · Musculoskeletal Diseases (77) · Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (25) · Neurologic Manifestations (24) · Pain (7) · Joint Diseases (6) · Mental Disorders (6) · Pathologic Processes (6) · Behavior (5) · Behavioral Symptoms (4) · Chronic Disease (4)
Pregabalin (18) · Duloxetine Hydrochloride (10) · Milnacipran (7) · mirogabalin (5) · Sodium Oxybate (4) · Cognitive Behavioral Therapy (3) · Gabapentin (2) · Sugars (2) · Transcranial Direct Current Stimulation (2) · cyclobenzaprine (2) · Acupuncture Therapy (1) · Cannabidiol (1) · Dexamethasone (1) · Drugs, Investigational (1) · Educational Status (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Eli Lilly and Company (7) · Tonix Pharmaceuticals, Inc. (7) · Daiichi Sankyo (5) · Forest Laboratories (4) · Jazz Pharmaceuticals (4) · Duke University (2) · Pierre Fabre Medicament (2) · University of Cincinnati (2) · University of Washington (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Beth Israel Medical Center (1) · Centers for Disease Control and Prevention (1) · Centre Hospitalier Universitaire, Amiens (1) · Centro Universitario La Salle (1)
United States (53) · Spain (13) · France (11) · Canada (10) · Germany (10) · United Kingdom (8) · India (7) · Italy (7) · Denmark (6) · Poland (6) · Portugal (6) · Sweden (6) · Czechia (5) · Netherlands (5) · Romania (5)
Gregory Sullivan, MD (3) · Jennifer M Hootman, PhD (2) · Alejandro Gugliucci, MD, PhD (1) · Allan Spera (1) · Ashwin A Patkar, MD (1) · Benjamin H Natelson, MD (1) · Daniel J. Clauw, MD (1) · Dennis C. Ang, MD (1)
PMID 26694975, PMID 31284771, PMID 21039311, PMID 21639874, PMID 22503162, PMID 21312349, PMID 15556826, PMID 15943960, PMID 17133529, PMID 18395345, PMID 19108787, PMID 19116896, PMID 19369473, PMID 20156949, PMID 20496365, PMID 20584327, PMID 20631018, PMID 20797382, PMID 20828282, PMID 21036635, PMID 21397402, PMID 21459941, PMID 21772818, PMID 21965636, PMID 22108765, PMID 22232085, PMID 22275142, PMID 22429066, PMID 22465047, PMID 22688598, PMID 23062189, PMID 23686969, PMID 24188161, PMID 24286114, PMID 24800123, PMID 24867298, PMID 25660434, PMID 25860107, PMID 26034150, PMID 26296539, PMID 26335989, PMID 26921267, PMID 27057659, PMID 30510505, PMID 31138224, PMID 31356450, PMID 33658841, PMID 35222735, PMID 36375174, PMID 37165930
2014 (1), 2019 (1), R01AR044724 (1), R01AR050028 (1), R01AR052368 (1), R01AT000004 (1)